stockrowApyx Medical Corporation
APYX Healthcare Medical Devices
Apyx Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $52.8 million, up 9.86% from fiscal 2024.
- Revenue
- +8.95%
- EPS
- +20.0%
- Free cash flow
- +53.2%
- Total debt
- +2.74%
Quarter to September 2026, against a year earlier
Follow APYX
Alert me
Apyx Medical Corporation (APYX) EV/Sales
As of 6 November 2026, Apyx Medical Corporation (APYX) trades at a EV/Sales of 2.5×. Over the past ten years it has ranged from 0.7× (November 2022) to 17.8× (September 2018); the current reading is higher than 35% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.9× | 111.00% |
| FY2024 | 1.4× | (19.52%) |
| FY2023 | 1.7× | 0.25% |
| FY2022 | 1.7× | (79.48%) |
| FY2021 | 8.4× | 14.14% |
| FY2020 | 7.4× | (9.32%) |
| FY2019 | 8.2× | (2.92%) |
| FY2018 | 8.4× | 168.30% |
| FY2017 | 3.1× | 22.54% |
| FY2016 | 2.6× | (25.74%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 2.1× | (41.85%) |
| Jun 2026 | 3.7× | 17.25% |
| Mar 2026 | 3.1× | 5.69% |
| Dec 2025 | 2.9× | 33.81% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CATX Perspective Therapeutics, Inc. compare | −339× |
| NYXH Nyxoah SA compare | 0.1× |
| OM Outset Medical, Inc. compare | 0.3× |
| OWLT Owlet, Inc. compare | 0.9× |
| LUNG Pulmonx Corporation compare | 1.1× |
| ZOMDF Zomedica Corp. compare | 1.3× |
| MXCT MaxCyte, Inc. compare | 1.3× |
| APYX Apyx Medical Corporation | 2.5× |
| LUCD Lucid Diagnostics Inc. compare | 11.3× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)